03-02-09

Express Mail Label No. ED 572755937 US Date of Deposit: February 28, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ICANTS:

Edinger et al.

SERIAL NUMBER:

09/997,425

EXAMINER:

Sullivan, Daniel M.

FILING DATE:

November 29, 2001

ART UNIT:

1636

For:

NOVEL ENDOZEPINE-RELATED PRECURSOR LIKE PROTEINS AND NUCLEIC

ACIDS ENCODING SAME (AS AMENDED)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Response to Office Action (13 pages); and
- 2. Appendix 1
- 3. Petition for Extension of Time (in duplicate)
- 4. Return postcard.

The Commissioner is hereby authorized to charge payment of any additional fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No.502648, Reference No.Cura 475 CIP

Respectfully submitted,

Mei L. Benni (Reg No. 45,470)

Attorney for Applicants

c/o CuraGen Corporation

555 Long Wharf Drive

New Haven, CT 06511

(203) 974-6303 phone

(203) 401-3351 fax

Dated: February 28, 2005

Attorney Docket No.: Cura-475 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Edinger et al. Confirmation No.: 6437

Application No.: 09/997,425 Group Art Unit: 1636

Filed: November 29, 2001 Examiner: Sullivan, Daniel M.

For: NOVEL ENDOZEPINE-RELATED

PRECURSOR LIKE PROTEINS AND NUCLEIC ACIDS ENCODING SAME

(AS AMENDED)

AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents P. O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In response to the Office Action mailed September 27, 2004, and in accordance with the Rules of Practice, please enter the following amendments and consider the remarks below. Attached hereto is Appendix 1: a ClustalW Alignment of SEQ ID NO: 2 and SEQ ID NO: 52 of the instant application. Applicants also submit herewith a Petition for Extension of Time for two month, up to and including February 28, 2005 (February 27, 2005 is a Sunday), with the required fee.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 6 of this paper.

Remarks begin on page 9 of this paper.